Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2004-02-25
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00005026
- Locations
- 🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 587
- Registration Number
- NCT00003299
- Locations
- 🇺🇸
CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
🇺🇸CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
- Conditions
- Interventions
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 308
- Registration Number
- NCT00003120
- Locations
- 🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸CCOP - Upstate Carolina, Spartanburg, South Carolina, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
- Conditions
- Locations
- 🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer
- Conditions
- First Posted Date
- 2004-02-19
- Last Posted Date
- 2011-03-24
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 40
- Registration Number
- NCT00003035
- Locations
- 🇺🇸
Lombardi Cancer Center, Washington, District of Columbia, United States
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 36
- Registration Number
- NCT00003582
- Locations
- 🇺🇸
Sylvester Cancer Center, University of Miami, Miami, Florida, United States
Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer
- Conditions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00006459
- Locations
- 🇺🇸
Office of Alex J.P. Makalinao, Los Angeles, California, United States
🇺🇸Danbury Internal Medicine, Danbury, Connecticut, United States
🇺🇸Comprehensive Cancer Care Specialists of Boca Raton, Boca Raton, Florida, United States
Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer
- Conditions
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 22
- Registration Number
- NCT00077129
- Locations
- 🇺🇸
Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States
🇺🇸Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States
🇺🇸Midwest Cancer Research Group, Incorporated, Skokie, Illinois, United States
Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung Cancer
- Conditions
- Locations
- 🇫🇷
Institut Sainte Catherine, Avignon, France
🇫🇷Centre Hospitalier Bayeux, Bayeux, France
🇫🇷Clinique Tivoli, Bordeaux, France
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
- Conditions
- First Posted Date
- 2004-02-09
- Last Posted Date
- 2020-07-14
- Target Recruit Count
- 12
- Registration Number
- NCT00003086
- Locations
- 🇺🇸
Louisiana State University School of Medicine, Shreveport, Louisiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.